tegafur/uracil / Generic mfg. - LARVOL DELTA

A pilot study of tegafur-uracil maintenance on survival in patients with esophageal squamous cell carcinoma following definitive chemoradiotherapy. (PubMed, Sci Rep) - "Multivariate analysis identified UFUR maintenance as an independent predictor of survival, alongside tumor stage and response to dCCRT. UFUR maintenance significantly improves outcomes in patients with ESCC following dCCRT, which might be considered as part of personalized treatment strategies to optimize prognosis in ESCC."

Journal • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

A Case of Urinary Retention Presenting as Oxaliplatin-Induced Acute Peripheral Neuropathy (PubMed, Gan To Kagaku Ryoho) - "The patient postoperatively received FOLFOX4+bevacizumab(BEV), followed by tegafur/uracil. Increased lymph node metastasis was observed 2 years prior, and treatment with tegafur/gimeracil/oteracil was initiated...The absence of urinary retention during the postoperative administration of FOLFOX4+BEV and its onset during the current administration of CAPOX+BEV may have been due to benign prostatic hyperplasia, which developed 5 years prior. Benign prostatic hyperplasia may be a risk factor for urinary retention in patients with acute peripheral neuropathy caused by L-OHP."

Journal • Benign Prostatic Hyperplasia • Colon Cancer • Colorectal Cancer • Oncology • Pain • Solid Tumor

Osimertinib-induced aplastic anemia after curative surgery for EGFR-mutant lung adenocarcinoma. (PubMed, Respir Med Case Rep) - "The patient had previously received adjuvant oral tegafur-uracil for 2 years without any hematologic toxicity...Treatment with cyclosporine led to gradual hematologic improvement and transfusion independence. This is a rare case of osimertinib-induced aplastic anemia occurring after curative-intent surgery for NSCLC, in contrast to previously published reports that mainly involved patients with advanced or metastatic disease. Clinicians should be aware of this rare but life-threatening complication and closely monitor peripheral blood counts during treatment, particularly within the first 2-8 months after treatment initiation."

Journal • Anemia • Aplastic Anemia • Hematological Disorders • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thrombocytopenia • EGFR

Efficacy of Tegafur-Uracil Maintenance Therapy in Non-Metastatic Head and Neck Squamous Cell Carcinoma: A Meta-Analysis With Trial Sequential Analysis. (PubMed, World J Oncol) - "However, these observations currently indicate only a possible trend and should not be regarded as definitive conclusions. Further prospective randomized controlled trials are required to validate the efficacy of UFT maintenance therapy and to establish standardized protocols for patient selection and dosing."

Journal • Retrospective data • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Innovative Treatment Modalities for Laryngeal and Hypopharyngeal Cancers (AAO-HNSF 2025) - "We will present a modified NACT protocol using split-dose docetaxel and cisplatin with oral tegafur/uracil (DCU), which effectively downstages advanced tumors and supports organ preservation...Includes surgical video presentations for surgical techniques.BACKGROUND STATEMENT: Patients with laryngeal and hypopharyngeal cancers require more treatment options that prioritize organ and function preservation while minimizing complications. This topic aims to inform the audience about various treatment strategies that can enhance their patients' quality of life.Comprehensive Otolaryngology Track Statement :"

Glottic Cancer • Head and Neck Cancer • Hypopharyngeal Cancer • Laryngeal Cancer • Oncology • Otorhinolaryngology • Solid Tumor

A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA (clinicaltrials.gov) - P3 | N=10 | Terminated | Sponsor: National Health Research Institutes, Taiwan | N=147 ➔ 10 | Enrolling by invitation ➔ Terminated; Recruiting progress behind expectation

Enrollment change • Trial termination • Head and Neck Cancer • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Tegafur-uracil as a Maintenance Therapy for Non-metastatic Nasopharyngeal Carcinoma: Insights from the Literature. (PubMed, Anticancer Res) - "However, trial sequential analysis indicated that the cumulative evidence did not meet the a priori information size required for a conclusive result, highlighting the need for further high-quality studies. In summary, UFT maintenance therapy may represent a promising option to reduce recurrence and improve survival in non-metastatic NPC, particularly in settings where access to novel agents is limited, but additional prospective studies are needed to confirm its clinical benefit."

Clinical • Journal • Review • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Adjuvant therapy in pStage IA1-IIA lung adenocarcinoma (pN0): A multicenter study focusing on EGFR mutations and recurrence patterns (CReGYT-01 EGFR study). (PubMed, Lung Cancer) - "Adjuvant UFT improves OS and RFS in EGFR wild-type pStage IA3-IIA lung adenocarcinoma, particularly in patients with high-risk pathological features. In contrast, UFT is ineffective in EGFR mutation-positive cases, highlighting the need for refined adjuvant treatment strategies tailored to EGFR status and tumor biology in early-stage lung adenocarcinoma with pathological N0 (pN0)."

Clinical • Journal • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Feasibility and efficacy of oral 5-FU in combination with pembrolizumab and cisplatin as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma: A prospective observational study. (ASCO 2025) - "Tegafur-Uracil, a substitute for 5-fluorouracil, was evaluated in combination with cisplatin and pembrolizumab as a first-line therapy. The findings suggest that Tegafur-Uracil combined with cisplatin and pembrolizumab offers a viable alternative for patients with poor baseline conditions, with an improved safety profile. Prospective studies are recommended to validate these results."

Clinical • Combination therapy • Metastases • Observational data • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Metronomic therapy as a favorable independent factor for survival in high-risk oral cavity squamous cell carcinoma. (ASCO 2025) - "For the group with metronomic therapy, oral tegafur-uracil was administered at a daily dose of 100-400mg per day, 28 days per month, and for one year after completing adjuvant chemoradiotherapy... Metronomic therapy significantly improved survival for high-risk OCSCC patients after completing curative therapy. Prospectively study is needed to be warranted."

Oncology • Oral Cancer • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Tegafur-Uracil Maintenance Therapy in Non-Metastatic Head and Neck Cancer: An Exploratory Systematic Review. (PubMed, Curr Oncol) - "While the evidence remains limited and heterogeneous, this review highlights recurring signals of benefit associated with UFT maintenance therapy in selected high-risk patients. Prospective trials are warranted to confirm these findings and better define a possible role of UFT in maintenance therapy in some advanced non-metastatic HNSCC and NPC."

Journal • Review • Head and Neck Cancer • Nasopharyngeal Carcinoma • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

UFUR maintenance therapy significantly improves survival in locally advanced head and neck squamous cell carcinoma following definitive chemoradiotherapy. (PubMed, Cancer Cell Int) - "UFUR maintenance therapy significantly improves survival outcomes in patients with advanced HNSCC following definitive chemoradiotherapy, particularly through enhanced locoregional control, and should be considered a key component of personalized treatment strategies."

Journal • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Evaluating the Benefits of TegafurUracil Adjuvant Therapy in LowRisk Stage IIa Colon Cancer: Insights from a DecadeLong Study (ASCRS 2025) - "If UFT is used as an ACT regimen for stage IIa colon cancer, a duration of more than one year is suggested.Overall Survival (OS) and Progression Free Survival (PFS) between No ACT group and UFT group.ACT: Adjuvant chemotherapy, UFT: Tegafur-uracilNo ACT group 5-year PFS: 71.7%, OS: 77%. UFT group 5-year PFS:83.9%, OS:87.9%.ROC Curve for UFT Treatment Duration and Overall Survival in low risk Stage IIa Colon Cancer PatientsAUC: Area Under the Curve, ROC: Receiver Operating Characteristic, UFT: Tegafur-Uracil.Optimal Cutoff ≤1.77, Sensitivity: 88.9%, Specificity: 38.4%."

Clinical • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor

Adjuvant therapy in stage IB non-small cell lung cancer: a network meta-analysis of tegafur-uracil and immune checkpoint inhibitors. (PubMed, Semin Thorac Cardiovasc Surg) - "In conclusion, tegafur-uracil may offer a comparable benefit to ICIs following chemotherapy in limitation to stage IB NSCLC patients only. Future clinical trials may be designed for stage IB NSCLC, separately from stage II and III."

Checkpoint inhibition • Journal • Retrospective data • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Preoperative chemoradiotherapy with the TEGAFIRI regimen achieves significant local control in locally advanced rectal cancer. (PubMed, Int J Colorectal Dis) - "The TEGAFIRI regimen for preoperative CRT in LARC demonstrated a high pCR rate and reduced local recurrence, with manageable adverse events."

Journal • Retrospective data • Colorectal Cancer • Oncology • Rectal Cancer • Solid Tumor

A multicenter retrospective study evaluating the effect of proton pump inhibitors on adjuvant tegafur-uracil/leucovorin efficacy for stage II-III colorectal cancer. (PubMed, Sci Rep) - "We hypothesized that there is reduced efficacy of fluorinated pyrimidines, such as capecitabine, caused by low active folic acid levels induced by vitamin B12 deficiency, due to proton pump inhibitors (PPIs), and that this can be recovered by the administration of leucovorin (LV). Cox regression analysis showed no significant differences in RFS between the PPI and non-PPI groups (hazard ratio, 1.16; 95% CI, 0.72-1.87; P = 0.539). Our findings suggest that the concomitant use of PPIs does not significantly reduce the efficacy of adjuvant UFT/LV treatment for patients with stage II/III CRC."

Journal • Retrospective data • Colorectal Cancer • Oncology • Solid Tumor

Tegafur-uracil maintenance chemotherapy post-chemoradiotherapy for cervical cancer: Randomized trial. (PubMed, Eur J Cancer) - "These findings suggest the need to reconsider maintenance therapy strategies after CCRT for potentially shifting away from cytotoxic chemotherapy towards alternative methods to enhance survival outcomes in patients with LACC."

Journal • Cervical Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

Efficacy of adjuvant tegafur-uracil (UFT) in early-stage non-small cell lung cancer with poor prognostic factors. (PubMed, Transl Lung Cancer Res) - "Postoperative adjuvant therapy with UFT significantly improved both RFS and OS in patients with stage IB/IIA NSCLC with poor prognostic factors. The administration of UFT should be considered in patients with high-risk early-stage NSCLC."

Biomarker • Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Gingival Metastasis After Surgery for Early-Stage Lung Adenocarcinoma. (PubMed, Ann Thorac Surg Short Rep) - "He received oral tegafur/uracil for adjuvant chemotherapy and visited our hospital every 2 months. Eleven months post-surgery, he presented with hemorrhage in his gingiva. A biopsy revealed that the gingival lesion was a metastasis from lung cancer."

Journal • Hematological Disorders • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Efficacy and safety of neoadjuvant chemohormonal therapy for high-risk prostate cancer treated with robot-assisted laparoscopic radical prostatectomy: a propensity score-matched analysis (the MSUG94 group). (PubMed, Int Urol Nephrol) - "The results suggest that NCHT can safely treat HR-PCa and may reduce the incidence of BCR when combined with RALP."

Journal • Genito-urinary Cancer • Hepatology • Oncology • Prostate Cancer • Solid Tumor

Sclerodermiform syndrome induced by antracyclines:case report (EADV 2024) - "Bleomycin, L -tryptophan, vinyl chloride and phytonadione (vitamin K1) have been reported, cases due to chemotherapeutic agents, such as taxane agents, gemcitabine and tegafur-uracil, and Immune checkpoint inhibitors have been reported. This undesirable skin effect is not recognized, it which delays the diagnosis. It is often confused initially with erysipelas, despite the absence of fever. We believe that this toxicity cutaneous must be recognized because of its seriousness potential."

Case report • Clinical • Breast Cancer • Dermatology • Erectile Dysfunction • Immunology • Oncology • Pain • Scleroderma • Systemic Sclerosis

The Effect of EGFR Mutation on Adjuvant Tegafur/Uracil for Patients with Non-Lymph Node Metastatic NSCLC (> 2 Cm) (IASLC-WCLC 2024) - "Introduction : The use of adjuvant osimertinib for epidermal growth factor receptor (EGFR) mutants is expected to expand to earlier stage I in the future, potentially competing with the current standard of care, oral tegafur/uracil (UFT), in Japan. In OS, EGFR mutation-positive was significant predictive factors in the univariable analysis (HR, 0.716: P = 0.024), however, the significance disappeared in the multivariable analysis. Conclusions : In pathologic stage I (>2 cm) lung adenocarcinomas with EGFR mutation, the survival benefit of adjuvant chemotherapy using UFT was not observed."

Clinical • Metastases • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Synergistic combination effect of the PCA-1/ALKBH3 inhibitor HUHS015 on prostate cancer drugs in vitro and in vivo. (PubMed, Anticancer Drugs) - "Herein, we investigated the effect of HUHS015 in combination with drugs for prostate cancer approved in Japan (including bicalutamide, cisplatin, mitoxantrone, prednisolone, ifosfamide, tegafur/uracil, docetaxel, dacarbazine, and estramustine) by treating DU145 cells with around IC50 value concentrations of these drugs for 3 days. In conclusion, HUHS015 exhibited a synergistic effect with docetaxel and drugs acting on DNA in vitro, even after drug removal. Since cancer chemotherapy is typically administered during rest periods due to its high toxicity, combining it with an ALKBH3 inhibitor could be a promising strategy for enhancing cancer treatment, as it can elicit an additive effect during treatment, allowing dosage reduction, and synergistically sustain the effect after drug washout during rest periods."

Journal • Preclinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

The effect of epidermal growth factor receptor mutation on adjuvant chemotherapy with tegafur/uracil for patients with completely resected, non-lymph node metastatic non-small cell lung cancer (> 2 cm): a multicenter, retrospective, observational study as exploratory analysis of the CSPOR-LC03 study. (PubMed, Jpn J Clin Oncol) - "In pathologic stage I (>2 cm) lung adenocarcinomas with EGFR mutation, the survival benefit of adjuvant UFT was not observed."

Journal • Metastases • Observational data • Retrospective data • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Relationship between Oncotype DX® test results and POTENT trial eligibility criteria (JBCS 2024) - "While it is difficult to expect chemotherapy to be effective based on Ki67, PgR expression is low, so oral administration of tegafur-uracil (covered by insurance) was added instead of endocrine therapy alone... Of the total 82 patients (median age 54 [33-78] years), 10 patients (12%, median RS 25 [0-32]) received standard infusion chemotherapy including anthracycline/taxane, and 72 patients (88%, RS 15 [0-29]) omitted infusion chemotherapy. Of the 82 cases, 57 cases (70%, RS16 [0-32]) were POTENT eligible, and of the 72 cases in which infusion chemotherapy was omitted, 48 cases (59%, RS14 [1-27]) were eligible. After the results of the POTENT study were published, there were 4 cases (4.9%, RS18 [12-27]) that were POTENT eligible in which infusion chemotherapy was omitted but S-1 was used in combination."

Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2